Cita APA (7a ed.)

(14851115), A. E. Z., (14851118), F. S. V., (14851121), R. D., (14851124), S. L. B., (14851127), K. K. B., (14851130), H. E., . . . (14851181), A. F. (2025). Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy.

Cita Chicago Style (17a ed.)

(14851115), Amr El Zawily, et al. Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy. 2025.

Cita MLA (9a ed.)

(14851115), Amr El Zawily, et al. Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy. 2025.